Abstract
Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone secreted by endocrine K-cells in response to nutrient absorption. In this study we have utilized a specific and enzymatically stable GIP receptor antagonist, (Pro3)GIP, to evaluate the contribution of endogenous GIP to insulin secretion and glucose homeostasis in mice. Daily injection of (Pro3)GIP (25 nmol/kg body weight) for 11 days had no effect on food intake or body weight. Non-fasting plasma glucose concentrations were significantly raised (p<0.05) by day 11, while plasma insulin concentrations were not significantly different from saline treated controls. After 11 days, intraperitoneal glucose tolerance was significantly impaired in the (Pro3)GIP treated mice compared to control (p<0.01). Glucose-mediated insulin secretion was not significantly different between the two groups. Insulin sensitivity of 11-day (Pro3)GIP treated mice was slightly impaired 60 min post injection compared with controls. Following a 15 min refeeding period in 18 h fasted mice, food intake was not significantly different in (Pro3)GIP treated mice and controls. However, (Pro3)GIP treated mice displayed significantly elevated plasma glucose levels 30 and 60 min post feeding (p<0.05, in both cases). Postprandial insulin secretion was not significantly different and no changes in pancreatic insulin content or islet morphology were observed in (Pro3)GIP treated mice. The observed biological effects of (Pro3)GIP were reversed following cessation of treatment for 9 days. These data indicate that ablation of GIP signaling causes a readily reversible glucose intolerance without appreciable change of insulin secretion.
References
Brown, J.C. (1994). Enteroinsular axis. In: Gut Peptides: Biochemistry and Physiology, G.J. Dockray and J.H. Walsh, eds. (New York, USA: Raven Press), pp. 765–784.Search in Google Scholar
Bunn, H.F., Haney, D.N., Gabbay, K.H., and Gallop, P.M. (1975). Further identification of the nature and linkage of the carbohydrate in hemoglobin A1c. Biochem. Biophys. Res. Commun.67, 103–109.10.1016/0006-291X(75)90289-2Search in Google Scholar
Burington, R.S. (1973). Handbook of Mathematical Tables and Formulae (New York, USA: McGraw-Hill).Search in Google Scholar
Creutzfeldt, W. (2001). The entero-insular axis in type 2 diabetes – incretins as therapeutic agents. Exp. Clin. Endocrinol. Diabetes109, S288–303.10.1055/s-2001-18589Search in Google Scholar PubMed
Dupré, J., Ross, S.A., Watson, D., and Brown, J.C. (1973). Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J. Clin. Endocrinol. Metab.37, 826–828.10.1210/jcem-37-5-826Search in Google Scholar PubMed
Eckel, R.H., Fujimoto, W.Y., and Brunzell, J.D. (1979). Gastric inhibitory polypeptide enhanced lipoprotein activity in cultured preadipocytes. Diabetes28, 1141–1142.10.2337/diab.28.12.1141Search in Google Scholar PubMed
Ehses, J.A., Casilla, V.R., Doty, T., Pospisilik, J.A., Winter, K.D., Demuth, H.U., Pederson, R.A., and McIntosh, C.H.S. (2003). Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology144, 4433–4445.10.1210/en.2002-0068Search in Google Scholar PubMed
Elahi, D., Meneilly, G.S., Minaker, K.L., Rowe, J.W., and Andersen, D.K. (1986). Regulation of hepatic glucose production by gastric inhibitory polypeptide in man. Abstracts presented at the sixth international symposium on gastrointestinal hormones in Vancouver, BC, Canada. Can. J. Physiol. Pharmacol.65 , pp. 18.Search in Google Scholar
Fehmann, H.C., Göke, R., and Göke, B. (1995). Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide. Endocrinol. Rev.16, 390–410.10.1210/edrv-16-3-390Search in Google Scholar PubMed
Flatt, P.R., and Bailey, C.J. (1981). Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia20, 573–577.10.1007/BF00252768Search in Google Scholar PubMed
Gault, V.A., O’Harte, F.P.M., Harriott, P., and Flatt, P.R. (2002a). Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem. Biophys. Res. Commun.290, 1420–1426.10.1006/bbrc.2002.6364Search in Google Scholar PubMed
Gault, V.A., Flatt, P.R., Bailey, C.J., Harriott, P., Greer, B., Mooney, M.H., and O’Harte, F.P.M. (2002b). Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant anti-hyperglycaemic activity in spontaneous obesity-diabetes. Biochem. J.367, 913–920.10.1042/bj20020319Search in Google Scholar PubMed PubMed Central
Gault, V.A., O’Harte, F.P., Harriott, P., Mooney, M.H., Green, B.D., and Flatt, P.R. (2003a). Effects of the novel (Pro3)GIP antagonist and exendin(9–39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic ob/ob mice: evidence that GIP is the major physiological incretin. Diabetologia46, 222–230.10.1007/s00125-002-1028-xSearch in Google Scholar PubMed
Gault, V.A., Flatt, P.R., and O’Harte, F.P.M. (2003b). Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem. Biophys. Res. Commun.308, 207–213.10.1016/S0006-291X(03)01361-5Search in Google Scholar
Gault, V.A., O’Harte, F.P., and Flatt, P.R. (2003c). Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential? Neuropeptides37, 253–263.10.1016/j.npep.2003.09.002Search in Google Scholar
Hansotia, T., Baggio, L.L., Delmeire, D., Hinke, S.A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J.J., Schuit, F., and Drucker, D.J. (2004). Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes53, 1326–1335.10.2337/diabetes.53.5.1326Search in Google Scholar
Hinke, S.A., Lynn, F., Ehses, J., Pamir, N., Manhart, S., Kuhn-Wache, K., Rosche, F., Demuth, H.U., Pederson, R.A., and McIntosh, C.H.S. (2003). Glucose-dependent insulinotropic polypeptide (GIP): development of DP IV-resistant analogues with therapeutic potential. Adv. Exp. Med. Biol.524, 293–301.Search in Google Scholar
Holst, J.J. (1994). Glucagon-like peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology107, 1848–1855.10.1016/0016-5085(94)90831-1Search in Google Scholar
Holst, J.J. (2002). Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1? BioDrugs16, 175–181.10.2165/00063030-200216030-00002Search in Google Scholar
Kieffer, T.J. (2003). GIP or not GIP? That is the question. Trends Pharmacol. Sci.24, 110–112.10.1016/S0165-6147(03)00031-2Search in Google Scholar
Knapper, J.M., Puddicombe, S.M., Morgan, L.M., and Fletcher, J.M. (1995). Investigations into the actions of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1(7–36) amide on lipoprotein lipase activity in explants of rat adipose tissue. J. Nutr.125, 183–188.Search in Google Scholar
Kosaka, T., and Lim, R.K.S. (1930). Demonstration of the humoral agent in fat inhibition of gastric secretion. Proc. Soc. Exp. Biol. Med.27, 890–891.10.3181/00379727-27-5024Search in Google Scholar
Meier, J.J., Nauck, M.A., Schmidt, W.E., and Gallwitz, B. (2002). Gastric inhibitory polypeptide: the neglected incretin revisited. Regul. Pept.107, 1–13.10.1016/S0167-0115(02)00039-3Search in Google Scholar
Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A. et al. (1999). Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knock-out mice. Proc. Nat. Acad. Sci. USA96, 14843–14847.10.1073/pnas.96.26.14843Search in Google Scholar PubMed PubMed Central
Nauck, M., Schmidt, W.E., Ebert, R., Strietzel, J., Cantor, P., Hoffmann, G., and Creutzfeldt, W. (1989). Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. J. Clin. Endocrinol. Metab.69, 654–662.10.1210/jcem-69-3-654Search in Google Scholar PubMed
Oben, J., Morgan, L.M., Fletcher, J., and Marks, V. (1991). Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7–36) amide, on fatty acid synthesis in explants of rat adipose tissue. J. Endocrinol.130, 267–272.10.1677/joe.0.1300267Search in Google Scholar
O’Harte, F.P.M., Gray, A.M., and Flatt, P.R. (1998) Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle. J. Endocrinol.156, 237–243.10.1677/joe.0.1560237Search in Google Scholar
Pamir, N., Lynn, F.C., Buchan, A.M., Ehses, J., Hinke, S.A., Pospisilik, J.A., Miyawaki, K., Yamada, Y., Seino, Y., McIntosh, C.H.S., and Pederson, R.A. (2003). Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. Am. J. Physiol. Endocrinol. Metab.284, E931–939.10.1152/ajpendo.00270.2002Search in Google Scholar
Pederson, R.A., Satkunarajah, M., McIntosh, C.H.S., Scrocchi, L.A., Flamez, D., Schuit, F., Drucker, D.J., and Wheeler, M.B. (1998). Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon like peptide 1 receptor –/– mice. Diabetes47, 1046–1052.10.2337/diabetes.47.7.1046Search in Google Scholar
Preitner, F., Ibberson, M., Franklin, I., Binnert, C., Pende, M., Gjinovci, A., Hansotia, T., Drucker, D.J., Wollheim, C., Burcelin, R., and Thorens, B. (2004). Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J. Clin. Invest.113, 635–645.10.1172/JCI200420518Search in Google Scholar
Stevens, J.F. (1971). Determination of glucose by an automatic analyser. Clin. Chem. Acta32, 199–201.10.1016/0009-8981(71)90332-9Search in Google Scholar
Trumper, A., Trumper, K., Trusheim, H., Arnold, R., Göke, B., and Horsch, D. (2001). Glucose-dependent insulinotropic polypeptide is a growth factor for β (INS-1) cells by pleiotropic signaling. Mol. Endocrinol.15, 1559–1570.10.1210/me.15.9.1559Search in Google Scholar
Trumper, A., Trumper, K., and Horsch, D. (2002). Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in β (INS-1)-cells. J. Endocrinol.174, 233–246.10.1677/joe.0.1740233Search in Google Scholar
Tseng, C-C., Boylan, M.O., Jarboe, L.A., Usdin, T.B., and Wolfe, M.M. (1996). Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats. Am. J. Physiol.270, E661–E666.10.1152/ajpendo.1996.270.4.E661Search in Google Scholar
Wang, Y., Montrose-Rafizadeh, C., Adams, L., Raygada, M., Nadiv, O., and Egan, J.M. (1996). GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN 1046–38 cells. Mol. Cell Endocrinol.116, 81–87.10.1016/0303-7207(95)03701-2Search in Google Scholar
Yip, R.G.C., Boylan, M.O., Kieffer, T.J., and Wolfe, M.M. (1998). Functional GIP receptors are present on adipocytes. Endocrinology139, 4004–4007.10.1210/endo.139.9.6288Search in Google Scholar PubMed
© Walter de Gruyter
